EGFR and glioma: Clinical trials of CAR T-cell therapy for gliomas have primarily focused on targeting TAAs such as IL-13 receptor alpha 2 (IL-13Rα2) [37], EGFR variant III (EGFRvIII) [61,62] and human EGFR 2 (HER2) [63].